stockrowGeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
Follow WGS
Alert me
GeneDx Holdings Corp. (WGS) EPS (diluted)
GeneDx Holdings Corp.'s EPS (diluted) for fiscal 2025 was −$0.73, compared with −$1.94 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$3.64. Over the past ten years it has ranged from −$7,905,874.00 (fiscal 2019) to −$0.73 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 6 consecutive fiscal years. GeneDx Holdings Corp. ranks 41st of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$0.73 | — |
| FY2024 | −$1.94 | — |
| FY2023 | −$7.23 | — |
| FY2022 | −$53.80 | — |
| FY2021 | −$74.92 | — |
| FY2020 | −$1,552,177.00 | — |
| FY2019 | −$7,905,874.00 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.60 | — |
| Mar 2026 | −$2.16 | — |
| Dec 2025 | −$0.61 | — |
| Sep 2025 | −$0.27 | — |
| 20 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| CDNA CareDx, Inc. compare | $2.39 |
| VCYT Veracyte, Inc. compare | $1.55 |
| OPK OPKO Health, Inc. compare | −$0.19 |
| NEO NeoGenomics, Inc. compare | −$0.25 |
| FRNM Freenome, Inc compare | −$0.31 |
| ADPT Adaptive Biotechnologies Corporation compare | −$0.45 |
| CSTL Castle Biosciences, Inc. compare | −$0.77 |
| PSNL Personalis, Inc. compare | −$1.17 |
| WGS GeneDx Holdings Corp. | −$3.64 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on WGS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement